PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 1 year 7 months ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 1 year 7 months ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 1 year 7 months ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 1 year 7 months ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE published on 09/27/2024 at 11:24, 1 year 8 months ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 1 year 8 months ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
PRESS RELEASE published on 09/23/2024 at 19:36, 1 year 8 months ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
Published on 06/03/2026 at 10:30, 2 hours 22 minutes ago Silver Range Partner Excalibur Metals Intersects a Broad Precious Metals Zone, Open at Depth at the Bellehelen Property
Published on 06/03/2026 at 10:00, 2 hours 52 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 09:01, 3 hours 51 minutes ago Apex Announces Drill Program Expansion and H2 Exploration Plans at the Rift Rare Earth Project
Published on 06/03/2026 at 04:58, 7 hours 54 minutes ago Snipp Interactive Reports Q1 2026 Financial Results; Bookings Backlog Reaches Record $20.6 Million; Announces Conference Call on Wednesday, June 3, 2026
Published on 06/03/2026 at 12:45, 7 minutes ago Hong Kong forges new opportunities with Kazakhstan and Central Asia
Published on 06/03/2026 at 12:40, 12 minutes ago Infosys and LTA Launch AI-Driven Match and Fan Experiences at the HSBC Championships, and Beyond
Published on 06/03/2026 at 12:18, 33 minutes ago RBI on the interim status of acceptances of the voluntary public tender offer for all Addiko shares as of 3 June 2026
Published on 06/03/2026 at 12:12, 40 minutes ago Worthington Steel Completes Acquisition of Kloeckner & Co and Announces Intention to Launch Delisting Tender Offer
Published on 06/03/2026 at 12:10, 42 minutes ago EQS-WpÜG: Tender Offer / Target company: Klöckner & Co SE; Bidder: Worthington Steel GmbH
Published on 06/03/2026 at 12:41, 11 minutes ago Disclosure of Share Capital and Voting Rights as of Mai 31, 2026
Published on 06/03/2026 at 11:29, 1 hour 23 minutes ago 2026.06.03 Notice to holders of the Convertible Bond ISIN FR0013521085
Published on 06/03/2026 at 08:45, 4 hours 7 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 18 hours 49 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 19 hours 10 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
